These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

284 related articles for article (PubMed ID: 9241709)

  • 1. Regulation of thrombin formation by activated protein C: effect of the factor V Leiden mutation.
    Tans G; Nicolaes GA; Rosing J
    Semin Hematol; 1997 Jul; 34(3):244-55. PubMed ID: 9241709
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Activated protein C resistance and thrombosis: molecular mechanisms of hypercoagulable state due to FVR506Q mutation.
    Dahlbäck B
    Semin Thromb Hemost; 1999; 25(3):273-89. PubMed ID: 10443959
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coagulation factor V: an old star shines again.
    Rosing J; Tans G
    Thromb Haemost; 1997 Jul; 78(1):427-33. PubMed ID: 9198191
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activated protein C resistance: molecular mechanisms.
    Griffin JH; Heeb MJ; Kojima Y; Fernández JA; Kojima K; Hackeng TM; Greengard JS
    Thromb Haemost; 1995 Jul; 74(1):444-8. PubMed ID: 8578503
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous factor V synthesis in megakaryocytes contributes negligibly to the platelet factor V pool.
    Thomassen MC; Castoldi E; Tans G; Magdeleyns EJ; Delaunoit C; Debusscher L; Van Assche KJ; Rosing J
    Haematologica; 2003 Oct; 88(10):1150-6. PubMed ID: 14555311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Factor V and protein S as cofactors to activated protein C.
    Dahlbäck B
    Haematologica; 1997; 82(1):91-5. PubMed ID: 9107093
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New molecular insights into the genetics of thrombophilia. Resistance to activated protein C caused by Arg506 to Gln mutation in factor V as a pathogenic risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1995 Jul; 74(1):139-48. PubMed ID: 8578447
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Resistance to activated protein C as risk factor for thrombosis: molecular mechanisms, laboratory investigation, and clinical management.
    Dahlbäck B
    Semin Hematol; 1997 Jul; 34(3):217-34. PubMed ID: 9241707
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Early days of APC resistance and FV Leiden.
    Dahlbäck B
    Hamostaseologie; 2008; 28(3):103-9. PubMed ID: 18521487
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Factor V and thrombotic disease: description of a janus-faced protein.
    Nicolaes GA; Dahlbäck B
    Arterioscler Thromb Vasc Biol; 2002 Apr; 22(4):530-8. PubMed ID: 11950687
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of hereditary and acquired risk factors of venous thrombosis on a thrombin generation-based APC resistance test.
    Curvers J; Thomassen MC; Rimmer J; Hamulyak K; van der Meer J; Tans G; Preston FE; Rosing J
    Thromb Haemost; 2002 Jul; 88(1):5-11. PubMed ID: 12152677
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Factor V enhances the cofactor function of protein S in the APC-mediated inactivation of factor VIII: influence of the factor VR506Q mutation.
    Váradi K; Rosing J; Tans G; Pabinger I; Keil B; Schwarz HP
    Thromb Haemost; 1996 Aug; 76(2):208-14. PubMed ID: 8865533
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mutation in blood coagulation factor V associated with resistance to activated protein C.
    Bertina RM; Koeleman BP; Koster T; Rosendaal FR; Dirven RJ; de Ronde H; van der Velden PA; Reitsma PH
    Nature; 1994 May; 369(6475):64-7. PubMed ID: 8164741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Identification and functional characterization of a novel F5 mutation (Ala512Val, FVB onn ) associated with activated protein C resistance.
    Pezeshkpoor B; Castoldi E; Mahler A; Hanel D; Müller J; Hamedani NS; Biswas A; Oldenburg J; Pavlova A
    J Thromb Haemost; 2016 Jul; 14(7):1353-63. PubMed ID: 27090446
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Congenital and acquired activated protein C resistance.
    Nicolaes GA; Dahlbäck B
    Semin Vasc Med; 2003 Feb; 3(1):33-46. PubMed ID: 15199491
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The second laminin G-type domain of protein S is indispensable for expression of full cofactor activity in activated protein C-catalysed inactivation of factor Va and factor VIIIa.
    Evenäs P; García de Frutos P; Nicolaes GA; Dahlbäck B
    Thromb Haemost; 2000 Aug; 84(2):271-7. PubMed ID: 10959700
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resistance to activated protein C caused by the R506Q mutation in the gene for factor V is a common risk factor for venous thrombosis.
    Dahlbck B
    J Intern Med Suppl; 1997; 740():1-8. PubMed ID: 9350175
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Molecular mechanisms of activated protein C resistance. Properties of factor V isolated from an individual with homozygosity for the Arg506 to Gln mutation in the factor V gene.
    Aparicio C; Dahlbäck B
    Biochem J; 1996 Jan; 313 ( Pt 2)(Pt 2):467-72. PubMed ID: 8573079
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Resistance to activated protein C caused by the factor VR506Q mutation is a common risk factor for venous thrombosis.
    Dahlbäck B
    Thromb Haemost; 1997 Jul; 78(1):483-8. PubMed ID: 9198201
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Structural investigation of the A domains of human blood coagulation factor V by molecular modeling.
    Villoutreix BO; Dahlbäck B
    Protein Sci; 1998 Jun; 7(6):1317-25. PubMed ID: 9655335
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.